Allarity Therapeutics (NASDAQ:ALLR) Releases Q4 2026 Earnings Guidance

Allarity Therapeutics (NASDAQ:ALLR) issued an update on its fourth quarter 2026 earnings guidance on Friday. The company provided EPS guidance of 0.010-0.040 for the period, compared to the consensus EPS estimate of -0.210. Allarity Therapeutics also updated its FY 2026 guidance to -0.760–0.730 EPS.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Allarity Therapeutics in a research report on Thursday, October 15th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Allarity Therapeutics presently has an average rating of “Hold” and an average price target of $10.25.

Allarity Therapeutics Trading Down 2.3%

NASDAQ:ALLR opened at $0.91 on Friday. The stock has a market capitalization of $14.54 million, a PE ratio of -1.17 and a beta of 0.57. Allarity Therapeutics has a 1-year low of $0.77 and a 1-year high of $1.84. The firm has a fifty day simple moving average of $1.02 and a 200 day simple moving average of $1.21.

Allarity Therapeutics (NASDAQ:ALLR) last announced its quarterly earnings results on Friday, November 13th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.18). The business had revenue of $0.01 million for the quarter. Allarity Therapeutics has set its FY 2026 guidance at -0.760–0.730 EPS and its Q4 2026 guidance at 0.010-0.040 EPS. On average, equities analysts predict that Allarity Therapeutics will post -0.80 earnings per share for the current fiscal year.

About Allarity Therapeutics

Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biotechnology company focused on developing personalized treatments for cancer. The company uses its Drug Response Predictor (DRP) technology to analyze patient and tumor characteristics and identify individuals who may be more likely to respond to specific drug candidates. Allarity’s development programs have included stenoparib, also known as 2X-121, an orally administered PARP inhibitor being investigated for potential use in oncology.